Introduction
A therapeutic goal in the treatment of cerebral ischemia is to restore blood flow to areas that are marginally perfused in the area of 'ischemic penumbra. ' The time course of this flow restoration is currently debated; however, stroke patients with a higher density of blood vessels are associated with less morbidity and longer survival. 1, 2 These results have demonstrated that angiogenesis actively progresses in the region of cerebral ischemia, and that the newly formed microvessel network is important for functional recovery of the brain from ischemic brain injury. Clinical observations have shown increased neovascularization colocalized with increased cerebral blood flow (CBF), suggesting that newly formed microvessels are functional. 3 Functional magnetic resonance imaging studies in stroke patients provide more evidence that several processes are involved in the restoration of neurological function. 2 Endogenous vascular endothelial growth factor (VEGF) appears to be insufficient to protect ischemic brain injury while an increase of exogenous VEGF following ischemia may induce this effect. [4] [5] [6] Angiogenesis is a step-by-step process that involves increase of vascular permeability, degradation of surrounding matrix, proliferation and migration of endothelial cells, and stabilization of newly formed microvessels. 7 It has been noted that angiogenesis takes at least 1-4 weeks, which is confirmed by increased CBF in the ischemic area. The function of newly formed microvessels in the adult brain after stroke is uncertain. [8] [9] [10] [11] [12] The concerted action of many angiogenic molecules is needed in this process, in which VEGF is the most important molecule in each step of angiogenesis. 13, 14 Controlling VEGF expression and maintaining a certain level of VEGF in the ischemic region appear to be crucial for focal angiogenesis. Since VEGF has a short half-life, repeated local multiple injection of VEGF protein in the ischemic region may cause further mechanical injury. VEGF protein cannot go through blood-brain barrier and also limits systemic administration. Gene transfer has the potential to maintain a sufficient concentration of VEGF protein over a long period of time from a single administration. Adeno-associated virus (AAV) vector, a single-stranded DNA virus and a nonpathogenic, helperdependent member of the parvovirus family, has several advantages over other viral vectors, e.g., immunogenicity, and the ability to mediate long-term transgene and infect both dividing and non-dividing cells. 15, 16 AAV-delivered VEGF gene has shown therapeutic potential for many ischemic diseases.
Because uncontrolled VEGF expression can induce some unwanted side effects such as hemangioma and synovium, 17, 18 controlling exogenous VEGF expression is crucial. Several inducible promoters have been used to control gene expression, such as tetracycline operons, RU 486, edyasone and other inducible systems. [18] [19] [20] [21] [22] [23] [24] [25] For the treatment of ischemic diseases, an ideal control would be the expression of angiogenic factors responding to hypoxia/ischemic. Hypoxia-inducible factor-1 (HIF-1) is a protein that accumulates in the tissue under hypoxic/ ischemia conditions. 26 When activated, HIF-1 binds to the hypoxia-responsive element (HRE) and upregulates the expression of several genes such as VEGF, erythropoietin, enolase and others. 27 HIF-1 acts as a sensor of ischemic conditions and may trigger the activation of angiogenesis associated with ischemic lesions.
Using AAVH9-VEGF vector, which carries nine copies of HRE isolated from a gene enhancer, 28 we explored whether conditional expression of VEGF, using tissue hypoxia/ischemia as a trigger, would promote focal angiogenesis in a mouse transient middle cerebral artery occlusion (tMCAO) model (Figures 1 and 2 ).
Results

HIF-1 expression increased after tMCAO in the mouse brain
Determining the time course and location of ischemiainduced HIF-1 expression is essential to the application of HRE-controlled gene expression. HIF-1a-positive staining could not be detected in the normal nonischemic brain. However, HIF-1a expression was detected after tMCAO in the ischemic hemisphere in both the perifocal and core region. HIF-1 distribution was found predominantly in the nuclear cell, including the endothelial cells of microvessels. HIF-1-positive staining could be detected following 1 day of tMCAO, and sustained up to 2 weeks in the ischemic middle cerebral artery territory ( Figure 3) . Thus, the expression of HIF-1 in the ischemic brain indicated that it would be feasible to use HRE to control angiogenic factor expression in the ischemic brain.
HRE controls lacZ gene expression following AAVH9 vector transduction
To determine if the HRE enhancer could conditionally control the lacZ expression in the ischemic brain, we compared the lacZ expression in the ischemic and nonischemic brain following AAV encoding b-galactosidase Figure 1 Structure of the three AAV vectors. Upper: AAV-lacZ; middle: AAVH9-VEGF; bottom: AAVH9-lacZ. AAV-lacZ, AAV encoding b-galactosidase gene; CMV, cytomegalovirus; HRE, hypoxia-responsive element; ITR, inserted terminal repeat; PA, SV40 polyadenylation signal; SV40pro, simian virus 40 promoter; VEGF, vascular endothelial growth factor; 9HRE, nine copies of HRE. Figure 2 Time course of the experimental design. The needle track of AAVH9-VEGF, AAVH9-lacZ and saline injection is pointed at the brain section (left). tMCAO, transient middle cerebral artery occlusion; d1 ¼ the day of AAV-vector brain injection; d6 (o. 1d) ¼ 6 days after AAV-vector brain injection and 1 day after tMCAO; d13 (o. 1w) ¼ 13 days after AAV-vector brain injection and 1 week after tMCAO; and d20 (o. 2w) ¼ 20 days after AAV-vector brain injection and 2 weeks after tMCAO. The brain was sectioned 2 mm distal from the front pole, which included the whole middle cerebral artery territory. CBF was monitored from immediate tMCAO to 2 weeks of reperfusion. Point P: focal CBF measured in the perifocal region; point C: focal CBF measured in the core region. Total and enlarged microvessels were counted 1 and 2 weeks after tMCAO. CBF, cerebral blood flow; tMCAO, transient middle cerebral artery occlusion; CTX, cortex. AAVH9-VEGF promotes angiogenesis F Shen et al gene (AAV-lacZ) and AAVH9-lacZ gene transduction. LacZ expression was observed in the non-ischemic brain in the AAV-lacZ, but not in AAVH9-lacZ-transduced mice, suggesting that H9 could conditionally control lacZ expression. LacZ-positive staining was detected in the AAVH9-lacZ-transduced mice only after tMCAO, which localized in the ischemic perifocal area and sustained up to 2 weeks of tMCAO (Figure 4 ), indicating that HRE enhancer could switch on lacZ expression under ischemic stimulation.
HRE switches on VEGF overexpression in the AAVH9-VEGF-transduced mouse brain VEGF is a potent and highly specific mitogen for endothelial cells, and induces focal angiogenesis during post-ischemic repairing process. To verify if VEGF expression increased after tMCAO in the AAVH9-VEGF-transduced mice, we performed western blot to demonstrate the pattern of VEGF expression. We found that VEGF protein was greatly increased in the ischemic perifocal region in the AAVH9-VEGF-transduced mice compared to the AAVH9-lacZ-transduced or salinetreated mice (Po0.05, Figures 5a and b) . Increased VEGF expression sustained at least 2 weeks in the ischemic brain tissue (Figure 5c ), suggesting that ischemiainduced-HIF-1 could trigger HRE actively expressing VEGF. To identify which cell types expressed VEGF protein after tMCAO in the AAVH9-VEGF-transduced mice, we performed double staining for VEGF with NeuN, GFAP and CD-31, accordingly. NeuN and GFAP were colocalized well with VEGF after AAVH9-VEGF gene transfer (Figure 5d ). These VEGF-positive cells were essentially located in the ischemic perifocal region and extended to the boundary zone of the ischemic core. Strong VEGF-positive staining could be observed in the whole cell body in the AAVH9-VEGF-transduced mice, suggesting that neurons and astrocytes were the main source of VEGF during tMCAO. There were no CD-31-positive cells that merged with VEGF-positive staining, indicating that endothelial cells might not be the source of VEGF in the AAVH9-VEGF-transduced mice.
VEGF expression following tMCAO promotes focal angiogenesis
To determine whether AAVH9-VEGF promoted angiogenesis during tMCAO in vivo, we counted the number of microvessels using a fluorescent CD-31-staining technique. We found that the number of CD-31-positive staining microvessels was significantly increased in the AAVH9-VEGF (133725 and 180729 per field)-treated mice compared to the AAVH9-lacZ (94720 and 118719 per field), saline (93718 and 119720 per field) or nonischemic control (71716 and 75717 per field) mice after 1 and 2 weeks of tMCAO (Figures 6a and b, Po0.05). Since vessel dilation was an apparent evidence of active angiogenesis, we therefore measured microvessel diameter following tMCAO in the AAVH9-VEGF-transduced mouse brain. We found that the number of enlarged microvessels (diameter bigger than 12 mm) is significantly increased in the AAVH9-VEGF-transduced compared to the AAVH9-lacZ-transduced or salinetreated mice after tMCAO (Figures 6c and d, Po0.05). Furthermore, we examined if these microvessels were newly formed following ischemia. We discovered that the number of proliferating cell nuclear antigen (PCNA)-positive cell was greatly increased in the AAVH9-VEGF-transduced mice compared to the AAVH9-lacZ-transduced and saline-treated mice ( Figure  7 , Po0.05). PCNA-positive cells were typically located in the same regions where angiogenesis was active.
VEGF expression increases regional CBF in AAVH9-VEGF-transduced mice
To examine if CBF was recovered better following AAVH9-VEGF gene transfer as compared to the control animals, we measured surface CBF using a laser Doppler flowmetry (LDF). There was no difference in surface CBF in the ischemic core or perifocal region before and during tMCAO among the AAVH9-VEGF, AAVH9-lacZ-transduced and saline-treated groups of mice (Table 1) . sCBF in the ischemic core and perifocal regions was decreased in all the three groups of animals during 45 min of tMCAO. As we expected, the sCBF was recovered better in the AAVH9-VEGF-transduced mice compared to the AAVH9-lacZ transduced and saline-treated mice after 1 and 2 weeks of tMCAO, especially in the ischemic perifocal region (Po0.05).
Discussion
Our current studies demonstrate the following: (1) HIF-1 expressed in the ischemic brain tissue up to 2 weeks after tMCAO; (2) lacZ expression was observed in the AAVH9-lacZ-transduced mouse brain only after ischemic injury; (3) the total of dilated microvessels increased in the ischemic boundary zone in AAVH9-VEGF-transduced mice after 1 and 2 weeks of tMCAO; (4) the increase in PCNA-positive microvessels in the AAVH9-VEGF-transduced mice is parallel to the increase in microvessel counts and (5) surface CBF measured by LDF recovered better in the AAVH9-VEGF-transduced mice compared to the control groups. Our findings indicate that expression of exogenous VEGF, controlled 
AAVH9-VEGF promotes angiogenesis
F Shen et al by novel nine copies of Epo HRE, effectively induces focal angiogenesis and improves regional CBF, which suggests that HRE is unique and functional and can switch on the target gene expression only when ischemia/hypoxia occurs. Transduction efficiency is crucial to gene therapy because of the limitation of viral vector particle diffusion after intracerebral injection. Our previous study demonstrated that the intraventricular gene transfer could effectively increase target protein in the brain tissue. 29 We injected AAVH9-lacZ vector into the lateral caudate putamen and the lateral ventricle. LacZ gene was not expressed in the normal brain but it was overexpressed after tMCAO in the AAVH9-lacZ-transduced mouse brain. This lacZ expression could be detected up to 2 weeks after tMCAO, suggesting that AAVH9 vector was capable of regulating and maintaining VEGF expression under ischemic stimulation. Since VEGF is a secreting protein, AAVH9-VEGF transduction affords ongoing synthesis and local release of VEGF protein, which then freely diffuses into the extracellular space. Local transfected neurons and astrocytes secrete VEGF protein, which can spread by diffusion as well as cerebrospinal fluid circulation. Higher focal VEGF expression efficiently induces focal angiogenesis in large areas of the ischemic brain.
VEGF is a pro-mitogenic growth factor, which expresses in endothelial cells, smooth muscle cells and adult cardiomyocytes. [30] [31] [32] VEGF drives angiogenesis in a wide variety of tissues and lesions including tumors, and can induce vasculogenesis in adult rat muscle. 18 We did not detect smooth muscle b-actin and CD31-double staining with multiple layers in AAVH9-VEGF-transduced mice, which might have been due to the short time course and low dose of VEGF treatment. 33, 34 VEGF is highly expressed in the brain and especially in the ischemic perifocal region. 32 Ischemia upregulates VEGF expression within hours after cerebral ischemia and is maintained for days to weeks. [35] [36] [37] [38] [39] [40] In our study, the number of total microvessels and dilated microvessels was significantly increased in the AAVH9-VEGFtransduced mice compared to control groups, indicating that endogenously expressed VEGF was insufficient to promote angiogenesis in the ischemic brain. Increased VEGF is associated with focal angiogenesis, which could promote local blood flow restoration. Post-ischemic angiogenesis can be part of a larger regenerative response to ischemia resulting in neurovascular unit repairing. Besides inducing angiogenesis, VEGF promotes neurogenesis in the ischemic brain. Injecting VEGF induces neurogenesis in the subgranular zone of the hippocampal dentate gyrus and the rostral AAVH9-VEGF promotes angiogenesis F Shen et al subventricular zone in rats following 1-3 days of MCAO. 5 However, further studies on VEGF function during cerebral ischemia are necessary since the experimental results of VEGF on the ischemic brain are still considered controversial.
VEGF expression is most prominent in the ischemic boundary zone, but consensus regarding its cellular localization is lacking. [35] [36] [37] [38] [39] [40] Increase of VEGF mRNA in neurons, astrocytes and endothelial cells is detected in both clinical human ischemic stroke 41 and experimental 
F Shen et al rodent ischemic brain. 42 We found that AAVH9-VEGFinduced VEGF expressed dominantly in neurons and astrocytes, but not in endothelial cells in the ischemic rodent brain. We further verified that VEGF-positive staining was observed in both cell cytoplasm and nuclear in the AAVH9-VEGF-transduced mice. These results indicated that transfected neurons and astrocytes could be the focal source of both endogenous and exogenous VEGF protein. Astrocytes surrounding the microvessels in the ischemic perifocal region strongly expressed VEGF, suggesting that they were accessible to AAV transfection. We did not detect VEGF expression in the endothelial cells, which confirmed results from other studies. 43, 44 Capillary regeneration initiates in the infarct boundary zone from 2 to 7 days of cerebral ischemia. 45 Morphological analysis has revealed enlarged and thin-walled vessels in the ischemic perifocal region, 46 indicating that focal angiogenesis is associated with the local neurovascular unit environment. We found that dilated microvessels greatly increased in the AAV encoding VEGF165 gene (AAV-VEGF)-transduced mouse brain following 1-2 weeks of tMCAO, demonstrating that capillary repairing and remodeling could sustain at least 2 weeks after ischemic injury.
We monitored regional CBF using LDF measurement, which is noninvasive, simple and fast. Two-dimensional spatiotemporal dynamics of CBF changes can be monitored during ischemia and reperfusion through an intact skull. This CBF measurement covers MCA territory especially for small animals such as mice. Published data have shown a linear relationship between CBF reduction and MCAO as measured by simultaneous LDF or 14C-IMP. 47, 48 We expressed the changes of CBF as a percentage by setting the baseline value as reference group for consistent measurement comparison at different time points. We found that AAVH9-VEGF improved CBF recovery in the perifocal cortex starting at 1 week of tMCAO, and that further recovery extended to the core area 2 weeks of tMCAO. This result suggests that the newly formed microvessels are functional although further studies using radioisotopes to detect and analyze regional CBF may be needed.
In our study, we focused on the role of HIF-1 in the induction of VEGF in the brain. Although HIF-2a plays an important role in mouse development, its function in adult life is not completely understood. HIF-1a and HIF-2a exhibit the same DNA consensus sequence within the HRE in the promoters of their target genes; therefore, both HIF-1a and HIF-2a activate HRE and Saline  98721  100724  100723  --6  AAVH9-lacZ  96717  96717  96718  --6  AAVH9-VEGF  100721  99722  99721  --6  Saline  97720  89719  -96724  -10  AAVH9-lacZ  97719  97719  -91717  -11  AAVH9-VEGF  96719  99718  -99720  -10  Saline  99721  91720  --98722  6  AAVH9-lacZ  97718  85716  --96718  6  AAVH9-VEGF  99719  93722  --99720  6 Abbreviations: AAV, adeno-associated virus; CBF, cerebral blood flow; tMCAO, transient middle cerebral artery occlusion; VEGF, vascular endothelial growth factor. Baseline=CBF measured before tMCAO; occlusion=at the time of MCA occluded; rep=reperfusion. N=number of animals, data are mean7s.d. *Po0.05, vs saline and AAVH9-lacZ groups.
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induce VEGF expression during cerebral ischemia. 49 In addition, hypoxia is not only the stimulator for the activation of HIF-1, but venous hypertension, pressure, stretch and motion also trigger HIF-1 expression in a variety of cells, including vascular smooth muscle cell, myocardium and joint chondrocytes. HIF-1 can also be induced by cytokines (interleukin-1), growth factors (tumor necrosis factor-a, transforming growth factor-b and insulin-like growth factor-1), hormones (insulin) and viruses. [50] [51] [52] Our results suggested that HIF-1 overexpression was caused by ischemia in the early stage of MCAO; however, it could be caused by other factors such as increased local cytokines, chemokines and growth factors in the later stage of MCAO.
Acute upregulation of VEGF is related to blood-brain barrier permeability leakage because VEGF is expressed primarily in the ischemic areas. It also contributes to blood-brain barrier disruption in the early stage of ischemia. 46 However, this minor blood-brain barrier leakage may be necessary for focal angiogenesis; nevertheless, combining treatment with other angiogenic factors to reduce blood-brain barrier disruption could be more beneficial than from VEGF treatment alone.
In conclusion, we have demonstrated that nine copies of HRE can conditionally switch on expression of lacZ and VEGF in vivo. Overexpressed VEGF functionally activates angiogenesis and improves focal CBF restoration in the ischemic brain. These results indicate that HIF-1/HRE provides a unique tool for controlling angiogenic gene expression, and that its application may be extended to treat other ischemic disorders in the brain.
Materials and methods
Construction and production of AAVH9-VEGF and AAVH9-lacZ vectors
To construct AAV vectors with HRE controlling VEGF or lacZ gene expression, nine copies of HRE were inserted into the pbgal-promoter plasmid (Clontech Inc., Palo Alto, CA, USA) containing the SV40 minimal promoter upstream of the lacZ gene. We cloned the expression cassette to an AAV vector between two inverted terminal repeats to generate the AAVH9-lacZ vector. To construct AAVH9-VEGF vector, we replaced the lacZ gene with human VEGF 165 cDNA. All vectors were packaged in AAV serotype 1 capsid. AAV viruses were generated by using three-plasmid cotransfection system (Figure 1 ). Viral vectors were purified and concentrated by CsCl gradient centrifuge and dialyses against HEPES buffer. 28, 53 The virus title was determined by dot blot analysis.
Experimental groups
The UCSF Institutional Animal Use and Care Committee approved all experimental procedures for the use of laboratory animals. The first experiment was designed to examine transduction efficiency. Two groups of adult male CD-1 mice weighing 30-35 g received AAVH9-lacZ and AAV-lacZ transduction (n ¼ 18 per group). Animals were killed 6, 13 and 20 days after gene transfer, and the brains were sectioned for X-gal staining. The second experiment was designed to study the effect of AAVH9-VEGF in promoting angiogenesis. Three groups of CD-1 mice were injected with AAVH9-VEGF, AAVH9-lacZ or saline (n ¼ 18 per group). Five days after AAV vector injection, the mice underwent 45 min of tMCAO followed by 1-14 days of reperfusion. The microvessel number and regional CBFs were examined to determine the effect of AAVH9-VEGF on angiogenesis (Figure 2 ).
AAV vector transduction in the mouse brain
The mice were anesthetized intraperitoneally using ketamine/xylazine 100/10 mg per kg body weight, and then placed in a stereotactic frame with a mouth holder (David Kopf Instruments, Tujunga, CA, USA). A burr hole was drilled in the pericranium 2 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture. A 10 ml Hamilton syringe was stereotactically inserted into both the lateral ventricle and caudate about 3.0 mm under the cortex. Five microliters of viral suspensions, containing 2 Â 10 9 genome copies of virus of AAVH9-VEGF, AAVH9-lacZ or AAV-lacZ; were injected into the left ventricle and caudate putamen at a rate of 0.2 ml min
À1
, based on a previous study. 54 The needle was then withdrawn after 15 min of injection, the hole was sealed and the wound closed. The animals were allowed to recover and return to their home cages.
tMCAO model and CBF measurement
Five days after the vector injection, the mice were anesthetized using 1.5% isoflurane in 70%/30% NO/ O 2 . Body temperature was maintained at 37.070.5 1C using a heating pad. The tMCAO method was described in our previous studies. 55 Briefly, the internal carotid artery was isolated and the pterygopalatine artery was ligated. Then a 2-cm length of 5-0 rounded dermalon suture was gently advanced from the external carotid artery to the beginning of the middle cerebral artery covering a distance of 10.070.5 mm. The middle cerebral artery was occluded for 45 min and reperfusion was performed by withdrawing the suture from the internal carotid artery to the common carotid artery. The regional CBF was monitored by laser Doppler flowmetry (Vasamedics, St Paul, MN, USA) with a small caliber probe of 0.7 mm diameter. The laser Doppler probe, held in a micromanipulator, was lowered until it was in contact with the surface of the mouse's skull bone. The point at 3.5 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture was considered as an ischemic core, while the point at 1.0 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture was considered an ischemic perifocal. Continuous digital displays of LDF values were averaged over 5-s intervals and recorded during the surgical procedure. The CBF was re-measured before euthanizing the animals, and CBF values were calculated and expressed as percentages of baseline values. 54, 56 Vascular morphology assessments Microvessel numbers were counted in images captured from these areas using NIH Image 1.63 software. The number of microvessels was calculated as the mean of the numbers obtained from the six pictures. Similarly, the dilated microvessels (diameter 410 mm) were counted in each section; and the number of dilated microvessels was calculated as the mean of the numbers obtained from the six pictures.
5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal) staining
After sacrifice, the animals were perfused with a fixation of 2% paraformaldehyde in 0.1 M PIPES pH 6.9. Twenty coronal sections were cut and fixed in 0.5% glutaraldehyde for 10 min, incubated in X-gal-staining solution (5 mmol l À1 K 3 Fe(CN) 6 , 5 mmol l À1 K 4 Fe(CN) 6 , 2 mmol l
À1
MgCl 2 , 0.01% sodium deoxycholate, 0.02% NP-40 and 1 mg ml À1 5-bromo-4-chloro-3-indolyl-b-D-galactoside in phosphate-buffered saline) for 2 h and photographed. The sections were counted and stained using an Eosin Y phloxine B stain solution.
Immunohistochemistry
After the experiment, the mice were perfused-fixated with 4% paraformaldehyde/phosphate-buffered saline solution. The brain was removed and embedded in Tissue-Tek OCT. To block nonspecific binding, coronal brain sections (20 mm) were cut and incubated with Laszlo's blocking solution (10 mM Trizma, 500 mM NaCl and 0.05% Tween-20, pH 7.6) for 1 h, washed with Trisbuffered saline Tween-20, and then incubated overnight with anti-HIF-1 (1:500 dilution, Santa Cruz Bio, Santa Cruz, CA, USA) in Tris-buffered saline Tween-20 at 4 1C. Biotin-conjugated secondary antibody, avidin-biotin enzyme reagent (Vector Labs, Burlingame, CA, USA), and 3,3 0 -diaminobenzidine were used to visualize the positive signal. After counterstaining with hematoxylin, the sections were dehydrated for further microscopic study. For double fluorescent staining of the CD31/ VEGF, GFAP/VEGF, NSE/VEGF and lectin/PCNA, sections were treated as above and incubated overnight with primary antibodies at 4 1C. Detailed information on primary antibodies is listed in Table 2 . Double-labeled sections were evaluated using a fluorescence microscope (Olympus, Sunnyvale, CA, USA) with a filter cube (excitation filter, 495 nm; suppression filter, 528 nm) for fluorescence, and another filter cube (excitation filter, 596 nm; suppression filter, 620 nm) for red color.
Statistical analysis
Parametric data in the AAVH9-VEGF, AAVH9-lacZ and saline-treated groups were compared using an one-way analysis of variance, followed by Fisher's protected least significant difference test, as appropriate. All data are presented as mean7s.d. A probability value of less than 5% was considered to be statistically significant.
Abbreviations
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